Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Invasive meningococcal disease is a worldwide problem with serious repercussions for those affected. Vaccination is recognized as the best way to combat it. The cost of vaccination is prohibitive in many low-resource settings at home and abroad. By harnessing the special immunologic properties of the skin, a dose reduction may be achieved by intradermal administration of the vaccine. The cost savings associated with dose reduction will increase availability of the vaccine.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Meningococcal C naive subjects are required to fulfill all of the following criteria:
Meningococcal C experienced subjects are required to fulfill all of the following criteria:
Exclusion criteria
Meningococcal C naïve subjects should not have:
Meningococcal C experienced subjects should not have:
Primary purpose
Allocation
Interventional model
Masking
12 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal